Recombinant Rabbit mAb for Neurofilament Light Chain Sandwich ELISA — Validated Capture & Detection Combination
Neurofilament light chain (NfL) is an exclusively neuronal structural protein that is released into cerebrospinal fluid and blood following neuroaxonal damage. Monitoring NfL levels provides a quantitative measure of neurodegeneration and treatment response across ALS, multiple sclerosis, Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
Sekbio offers a validated recombinant rabbit mAb antibody pair for NfL sandwich ELISA development. NFL-w279 (capture) and NFL-w280 (detection) are the only validated combination in head-to-head screening — their non-overlapping epitope binding enables robust sandwich signal generation in human and mouse sample matrices.
Both antibodies are produced using Sekbio's recombinant expression platform, delivering consistent lot-to-lot performance essential for commercial IVD kit manufacturing and regulatory submissions.
Systematic head-to-head screening identified one functional sandwich ELISA combination. Only NFL-w279 (capture) paired with NFL-w280 (detection) produces a positive signal.
| Capture ↓ / Detection → | NFL-w279 (Detection) | NFL-w280 (Detection) |
|---|---|---|
| NFL-w279 (Capture) | — | ✓ Validated |
| NFL-w280 (Capture) | — | — |
| ✓ = Positive sandwich ELISA signal confirmed. — = No signal detected. Validated pair: NFL-w279 (capture) + NFL-w280 (detection). | ||
NfL is the most broadly validated blood-based biomarker of neuroaxonal damage — relevant across the full spectrum of neurological disease.
NfL is expressed exclusively in neurons — it is not produced by glial cells, astrocytes, or peripheral tissues. Elevated blood NfL directly indicates neuroaxonal damage, with no confounding signal from non-neuronal injury. The antibody pair does not cross-react with GFAP, enabling co-measurement in multiplex panels.
Under normal conditions, NfL is released at low baseline levels from axons. This rate increases significantly with age and accelerates following neuroaxonal damage — making NfL a sensitive, quantitative indicator of neurodegeneration rate. Blood NfL concentrations correlate with CSF levels and disease severity scores across multiple conditions.
NfL levels decline in response to effective neuroprotective therapy — making it a pharmacodynamic biomarker for clinical trials and disease-modifying treatment monitoring. This dual role (diagnosis + treatment monitoring) gives NfL-based IVD tests a broad addressable market across neurology, oncology, and critical care.
NfL can be detected in both cerebrospinal fluid (ng/mL range) and peripheral blood (pg/mL range). Blood-based measurement is particularly valuable as it enables non-invasive, longitudinal monitoring without lumbar puncture — a key advantage for point-of-care and routine clinical testing applications.
Elevated NfL is documented across ALS, multiple sclerosis, Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, traumatic brain injury, and stroke. A single NfL assay addresses a large clinical testing volume across neurology and critical care departments.
The NFL-w279/w280 antibody pair does not recognize GFAP (Glial Fibrillary Acidic Protein), the primary astrocyte biomarker that is often co-measured in neurological panels. This specificity enables development of multiplex NfL + GFAP assays on the same platform without signal interference between the two biomarkers.
NfL antibody pair validated for sandwich ELISA kit development across a wide range of neurological testing indications.
NfL elevation is a consistent finding across ALS, Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and Huntington's disease. ELISA kits incorporating the NFL-w279/w280 pair enable quantitative NfL measurement in serum, plasma, and CSF for clinical differential diagnosis and disease staging.
Blood NfL is an established pharmacodynamic biomarker in MS clinical trials. NfL levels correlate with relapse activity and MRI lesion burden, and decline in response to disease-modifying therapies. An NfL sandwich ELISA enables routine treatment monitoring without requiring lumbar puncture for CSF collection.
Blood NfL rises rapidly following traumatic brain injury and correlates with injury severity. NfL-based ELISA kits support acute TBI severity stratification in emergency settings, as well as longitudinal monitoring of recovery and detection of secondary neurological injury in ICU patients.
The NFL-w279/w280 antibody pair is available as OEM raw material for ELISA kit manufacturers. The validated capture/detection combination eliminates the screening phase of assay development, allowing kit developers to proceed directly to calibration and performance characterization — reducing development timelines by 4–8 weeks.
Both antibodies share identical buffer formulation and storage conditions, simplifying lot management in kit manufacturing workflows.
| Parameter | NFL-w279 (Capture) | NFL-w280 (Detection) |
|---|---|---|
| Catalog Number | NFL-w279 | NFL-w280 |
| Immunogen | Recombinant Protein | Recombinant Protein |
| Host / Isotype | Rabbit IgG | Rabbit IgG |
| Concentration | 2 mg/mL | 2 mg/mL |
| Purity | >95% by HPLC | >95% by HPLC |
| Purification Method | Protein A | Protein A |
| Physical Form | Liquid | Liquid |
| Buffer | PBS pH7.4, 0.03% Proclin 300 | PBS pH7.4, 0.03% Proclin 300 |
| Storage Temperature | 2–8°C | 2–8°C |
| Shelf Life | 12 months from receipt | 12 months from receipt |
| Species Reactivity | Human, Mouse | Human, Mouse |
| Cross-Reactivity | Does not recognize GFAP | Does not recognize GFAP |
The only validated combination is NFL-w279 as the capture antibody and NFL-w280 as the detection antibody in a sandwich ELISA format. All other combinations (NFL-w279 detection, NFL-w280 capture, or same-clone pairs) showed no signal in head-to-head screening. Both antibodies must be used together to generate a functional sandwich assay.
The NFL-w279/w280 pair shows reactivity with human (Hu) and mouse (Ms) neurofilament light chain. Primary sample types are cerebrospinal fluid (CSF) and blood-based matrices (serum/plasma). Performance in specific sample types and dilution conditions should be optimized during assay development for your target application.
No. Both NFL-w279 and NFL-w280 were confirmed to have no cross-reactivity with GFAP (Glial Fibrillary Acidic Protein). This makes the pair suitable for use in duplex or multiplex panels where NfL and GFAP are co-measured — a clinically relevant combination for TBI and neurodegeneration panels.
Both antibodies are supplied at 2 mg/mL in PBS pH7.4 with 0.03% Proclin 300. Storage at 2–8°C provides a shelf life of 12 months from the date of receipt. Aliquoting into single-use volumes is recommended to avoid repeated freeze-thaw cycles, which can reduce antibody activity over time.
Yes. As recombinant monoclonal antibodies produced under Sekbio's ISO 13485-certified manufacturing process, NFL-w279 and NFL-w280 are available for OEM supply with Certificate of Analysis, HPLC purity data, and lot-to-lot consistency records. Custom concentrations, buffer formulations, and conjugation services are available on request.
Request the NFL-w279/w280 antibody pair technical datasheet, ELISA optimization guide, or a sample for evaluation.